# A Study of Orelabrutinib in Patients With Primary Progressive Multiple Sclerosis

> **NCT07067463** · PHASE3 · RECRUITING · sponsor: **Zenas BioPharma (USA), LLC** · enrollment: 705 (estimated)

## Conditions studied

- Multiple Sclerosis (MS) Primary Progressive

## Interventions

- **DRUG:** Orelabrutinib
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07067463
- **Lead sponsor:** Zenas BioPharma (USA), LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-03-23
- **Primary completion:** 2030-06
- **Final completion:** 2030-07
- **Target enrollment:** 705 (ESTIMATED)
- **Last updated:** 2026-05-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07067463

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07067463, "A Study of Orelabrutinib in Patients With Primary Progressive Multiple Sclerosis". Retrieved via AI Analytics 2026-05-21 from https://api.ai-analytics.org/clinical/NCT07067463. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*